litlas
ログインアカウント作成

Zhendong Chen

2004–2026 年に発表

別表記
ZhenDong Chen
131
論文数
18,194
被引用数
40
h 指数
94
i10 指数

被引用数

Zhendong Chen の年別被引用数1979 年: 被引用 1 件1986 年: 被引用 1 件1989 年: 被引用 1 件2002 年: 被引用 1 件2004 年: 被引用 2 件2005 年: 被引用 3 件2006 年: 被引用 2 件2007 年: 被引用 3 件2008 年: 被引用 7 件2009 年: 被引用 23 件2010 年: 被引用 59 件2011 年: 被引用 58 件2012 年: 被引用 89 件2013 年: 被引用 66 件2014 年: 被引用 81 件2015 年: 被引用 83 件2016 年: 被引用 66 件2017 年: 被引用 87 件2018 年: 被引用 81 件2019 年: 被引用 308 件2020 年: 被引用 517 件2021 年: 被引用 664 件2022 年: 被引用 888 件2023 年: 被引用 775 件2024 年: 被引用 1,530 件2025 年: 被引用 856 件2026 年: 被引用 18 件1980〜1985 年は被引用が無いため表示していません1987〜1988 年は被引用が無いため表示していません1990〜2001 年は被引用が無いため表示していません2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 2,416 件、この内訳の 29.9%アメリカ合衆国: 引用元論文 1,244 件、この内訳の 15.4%日本: 引用元論文 477 件、この内訳の 5.9%イタリア: 引用元論文 439 件、この内訳の 5.4%韓国: 引用元論文 296 件、この内訳の 3.7%ドイツ: 引用元論文 293 件、この内訳の 3.6%イギリス: 引用元論文 285 件、この内訳の 3.5%フランス: 引用元論文 257 件、この内訳の 3.2%台湾: 引用元論文 257 件、この内訳の 3.2%スペイン: 引用元論文 249 件、この内訳の 3.1%カナダ: 引用元論文 156 件、この内訳の 1.9%香港: 引用元論文 152 件、この内訳の 1.9%
0%29.9%その他 19.3%

機関

分野

  • Medicine78.8%
  • Biochemistry, Genetics and Molecular Biology12.2%
  • Engineering2.8%
  • Immunology and Microbiology2.5%
  • Computer Science1%
  • Materials Science0.6%
  • その他2.1%

トピック

  • Hepatocellular Carcinoma Treatment and Prognosis12.7%
  • Cancer Immunotherapy and Biomarkers8.5%
  • Lung Cancer Research Studies4.9%
  • Cholangiocarcinoma and Gallbladder Cancer Studies4%
  • Cancer Mechanisms and Therapy3.6%
  • Lung Cancer Treatments and Mutations2.8%
  • その他63.5%

共著者

全論文

検索で開く
  1. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    著者: Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz ほか 146 名 - The Lancet 2019 被引用: 2,199

  2. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

    著者: Shukui Qin, Stephen L. Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Davide Melisi, Yurii Osypchuk, Ivan Sinielnikov, Tsai‐Sheng Yang, Liang Xiao, Chunxia Chen, Linna Wang, Linna Wang, Ahmed O. Kaseb, Arndt Vogel, Shukui Qin, Shukui Qin, Shukui Qin, Ahmed O. Kaseb, Arndt Vogel, Shanzhi Gu, Arndt Vogel, Zhenggang Ren, Xiaoyan Lin, Zhenggang Ren, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Jianping Xiong, Wei Li, Yajin Chen, Yong Zeng, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Margaryta Pisetska, Yurii Osypchuk, Ivan Sinielnikov, Tsai‐Sheng Yang, Liang Xiao, Chunxia Chen, Linna Wang, Mingxiang Zhang, Li Xu, Xianglin Yuan, Da Li, Jierer Ying, Jingdong Zhang, Tao Zhang, Kangsheng Gu, Yifu He, Kangsheng Gu, Da Jiang, Shu Zhang, Baocai Xing, Baihong Zhang, Dong Wang, Xiaofeng Zhai, Houjie Liang, Bożena Cybulska-Stopa, Mikhail Dvorkin, Daniil Stroyakovskiy, M. Nechaeva, Chia‐Jui Yen, Wei‐Wen Su, Yen‐Hao Chen, Igor Bondarenko, Lin Yang, Weijia Fang, Carlos Gómez-Martín, Min‐Hee Ryu, Hansang Kim, Jeehyun Kim, Oleg Zarubenkov ほか 38 名 - The Lancet 2023 被引用: 679

  3. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

    著者: Zhenggang Ren, Jianming Xu, Yuxian Bai, Aibing Xu, Shundong Cang, Chengyou Du, Qiu Li, Yinying Lu, Yajin Chen, Yabing Guo, Zhendong Chen, Baorui Liu, Weidong Jia, Jian Wu, Junye Wang, Guoliang Shao, Bixiang Zhang, Yunfeng Shan, Zhiqiang Meng, Jianbing Wu, Shanzhi Gu, Wei Yang, Chao Liu, Xuetao Shi, Zhenyuan Gao, Tao Yin, Jiuwei Cui, Ming Huang, Bao-Cai Xing, Yilei Mao, Gao‐Jun Teng, Yanru Qin, Jinhai Wang, Feng Xia, Guowen Yin, Yong Yang, Mingxia Chen, Yan Wang, Hui Zhou, Jia Fan - The Lancet Oncology 2021 被引用: 1,115

  4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

    著者: Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Sheng‐Long Ye, Tsai‐Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jiejun Wang, Won Young Tak, Hongming Pan, K. Burock, Jessie Zou, D. Voliotis, Zhongzhen Guan - The Lancet Oncology 2008 被引用: 5,842

  5. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

    著者: Shukui Qin, Minshan Chen, Ann‐Lii Cheng, Ahmed O. Kaseb, Masatoshi Kudo, Han Chu Lee, Adam C. Yopp, Jian Zhou, Lu Wang, Xiaoyu Wen, Jeong Heo, Won Young Tak, Shinichiro Nakamura, Kazushi Numata, Thomas Uguen, David Hsiehchen, Edward Cha, Stephen P. Hack, Qinshu Lian, Ning Ma, Jessica Spahn, Yulei Wang, Lyndia C. Wu, Pierce K. H. Chow, Alexander Thompson, Mark Danta, Pirooz Poursoltan, Andrew Ddembe Kiberu, Renuka Chittajallu, Siddarth Sood, Rudolf Stauber, Matthias Pinter, Markus Peck‐Radosavljevic, Jochen Decaestecker, Pieter‐Jan Cuyle, Gontran Verset, Hans Van Vlierberghe, Sérgio de Azevedo, Livia Andrade, Ademar Cunha Júnior, Luiza Dib Batista Bugiato Faria, Cheng Tzu Yen, Leandro M. Colli, Jamil Asselah, Petr Kavan, Vladimir Marquez, Mayur Brahmania, Qiang Li, Bao-Cai Xing, Yabing Guo, Zhendong Chen, Haitao Zhao, Tao Peng, Liming Wang, Lu Wang, Hongming Liu, Feixiang Wu, Lun–Xiu Qin, Qichang Zheng, Jieer Ying, Haitao Li, Tianfu Wen, Shukui Qin, Xiaoyu Wen, Yunpeng Liu, Minshan Chen, Boqing Wang, Yuxian Bai, Yifu He, Hong Zhao, Dong Zhou, Chaoliu Dai, Gao‐Jun Teng, Shuzhong Cui, Yi Gao, Xizhi Zhang, Zheng Lu, Tao Yin, Youming Ding, Weidong Jia, Yongxiang Xia, Beicheng Sun, Qiang Xia, Yufeng Yuan, Hui‐Chuan Sun, Xuetao Shi, A. Guzmán, Luis Corrales, Zdeněk Král, Peter Priester, Eugen Kubala, Jean Frédéric Blanc, Marc Bourlière, Jean Marie Péron, Christophe Borg, Jean–Pierre Bronowicki, Nathalie Ganne, Thomas Decaens, Thomas Uguen, Alexandra Heurgué ほか 109 名 - The Lancet 2023 被引用: 488

  6. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

    著者: Hui Luo, Jin Lü, Yuxian Bai, Teng Mao, Jun Wang, Qingxia Fan, Yiping Zhang, Kuaile Zhao, Zhendong Chen, Shegan Gao, Jiancheng Li, Zhichao Fu, Kangsheng Gu, Zhihua Liu, Lin Wu, Xiaodong Zhang, Ji‐Feng Feng, Zuoxing Niu, Yi Ba, Helong Zhang, Ying Liu, Li Zhang, Xuhong Min, Jing Huang, Ying Cheng, Dong Wang, Yu Shen, Qing Yang, Jianjun Zou, Rui‐Hua Xu, ESCORT-1st Investigators, Xianglin Yuan, Dong Ma, Emily Liu, Feng Ye, Tianshu Liu, Xiuwen Wang, Likun Liu, Bing Xia, Fengming Ran, Sanyuan Sun, Zhanhui Miao, Jun Bie, Yong Gao, Junyan Yu, Li Chen, Yifu He, Wei Ren, Suxia Luo, Guangqiang Zhao, Youen Lin, Long Chen, Zhiyuan Guo, Chunhong Hu, Ying Wang, Nong Xu, Baofu Chen, Xianbao Zhan, Yuping Chen, Hongda Lu, Shukui Qin, Guolei Wang, Liming Chen, Li Bai, Jingdong Zhang - JAMA 2021 被引用: 801

  7. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

    著者: Ying Cheng, Liang Han, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Mikhail Dvorkin, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Wenying Kang, Qingyu Wang, Jun Zhu, ASTRUM-005 Study Group, Xiubao Ren, Vladimer Kuchava, Guoping Sun, Gaofeng Li, Lin Wen, Tao Zhang, Hakan Harputluoğlu, İrfan Çiçin, Guosheng Feng, Yanrong Hao, Kejing Ying, Ping Sun, Aihong Zhong, Guangyu An, Yan Wang, Chun Chen, Sheng Yang, Zhendong Chen, Konstantin Penkov, Yuriy Semegen, Oleg Kobziev, Feng Luo, Peiguo Cao, Zhixiong Yang, Min Fan, Wen Li, Robert Mróz, А. Л. Акопов, Tuncay Göksel, Mahmut Gümüş, Wenlei Zhuo, Jian Fang, Hui Zhao, Lin Zhong, Yanping Hu, Yarong Li, Shuqun Zhang, Jiuwei Cui, Н. В. Коваленко, Çağatay Arslan, Devrim Cabuk, Alev Türker, Igor Bondarenko, Yevhen Hotko, O. Goloborodko, Dongji Chen, Mengzhao Wang, Zhuang Yu, Jun‐Guo Lu, Liyan Jiang, Hao Xiong, Davit Giorgadze, Sergey Orlov, Ahmet Bılıcı, Ivan Sinelnikov, Gongyan Chen, Yue Lu, Xiaoli Zhu, Liqin Lu, Mariam Zhvania, Małgorzata Ułańska, Igor Lifirenko, Timur Andabekov, Maria Smagina, Fedor Moiseenko, Yüksel Ürün, Ligong Nie, Bangwei Cao, Zhenyu You, Haixin Huang, Shenpeng Ying, Alexandre Tavartkiladze, Tariel Kitiashvili, Amiran Matitashvili ほか 9 名 - JAMA 2022 被引用: 456

  8. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

    著者: Zixian Wang, Chengxu Cui, Jun Yao, Yanqiao Zhang, Mengxia Li, Ji‐Feng Feng, Shujun Yang, Yun Fan, Jianhua Shi, Xizhi Zhang, Lin Shen, Yongqian Shu, Cailian Wang, Tianyang Dai, Teng Mao, Long Chen, Zengqing Guo, Bo Liu, Hongming Pan, Shundong Cang, Yi Jiang, Junye Wang, Min Ye, Zhendong Chen, Da Jiang, Qin Lin, Wei Ren, Junsheng Wang, Lin Wu, Yong Xu, Zhanhui Miao, Meili Sun, Conghua Xie, Ying Liu, Qifeng Wang, Lina Zhao, Qi Li, Canhong Huang, Ke Jiang, Kunyu Yang, Daojun Li, Yunpeng Liu, Zhitu Zhu, Rixin Chen, Liqun Jia, Wei Li, Wangjun Liao, Hongxu Liu, Daiyuan Ma, Jie Ma, Yanru Qin, Zhihong Shi, Qichun Wei, Ke Xiao, Yan Zhang, Ying Zhang, Xin Chen, Guanghai Dai, Jianxing He, Junhe Li, Guanghui Li, Yong Liu, Zhihua Liu, Xianglin Yuan, Junping Zhang, Zhichao Fu, Yifu He, Fang Ju, Zheng Liu, Peng Tang, Tiejun Wang, Weibo Wang, Jing Zhang, Xianming Luo, Xiongwen Tang, Rena May, Hui Feng, Sheng Yao, Patricia Keegan, Rui‐Hua Xu, Feng Wang - Cancer Cell 2022 被引用: 565

  9. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

    著者: Jing Huang, Jianming Xu, Yun Chen, Wu Zhuang, Yiping Zhang, Zhendong Chen, Jia Chen, Helong Zhang, Zuoxing Niu, Qingxia Fan, Lizhu Lin, Kangsheng Gu, Ying Liu, Yi Ba, Zhanhui Miao, Xiaodong Jiang, Ming Zeng, Jianhua Chen, Zhichao Fu, Lu Gan, Jun Wang, Xianbao Zhan, Tianshu Liu, Zhiping Li, Lin Shen, Yongqian Shu, Tao Zhang, Qing Yang, Jianjun Zou, Suxia Luo, Feng Peng, Gang Wu, Nong Xu, Lin Zhao, Dong Ma, Shukui Qin, Wei Ren, Enxiao Li, Hongda Lu, Yueyin Pan, Jianping Xiong, Ying Yuan, Yuxian Bai, Lei Chen, Yi Hu, Li Zhang, Yong Gao - The Lancet Oncology 2020 被引用: 584

  10. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

    著者: Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek‐Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaoming Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao - Journal of Clinical Oncology 2022 被引用: 189

  11. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

    著者: Shukui Qin, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang, Xiaoyan Lin, Xiaoming Chen, Enxiao Li, Linna Wang, Chunxia Chen, Jianjun Zou - The Lancet Oncology 2020 被引用: 638

  12. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

    著者: Shukui Qin, Feng Bi, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Chengxu Cui, Bo Zhu, Jian Wu, Xiaoli Xin, Jufeng Wang, Jinlu Shan, Junhui Chen, Zhendong Zheng, Li Xu, Xiaoyu Wen, Zhenyu You, Zhenggang Ren, Xiufeng Liu, Meng Qiu, Liqing Wu, Feng Chen - Journal of Clinical Oncology 2021 被引用: 414

  13. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

    著者: Lin Shen, Ken Kato, Sung‐Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Longzhen Zhang, Tienan Yi, Jong‐Mu Sun, Jianhua Chen, Guohua Yu, Chen‐Yuan Lin, Hiroki Hara, Qing Bi, Taroh Satoh, Roberto Pazo-Cid, Hendrick-Tobias Arkenau, Christophe Borg, Florian Lordick, Liyun Li, Ningning Ding, Aiyang Tao, Jingwen Shi, Eric Van Cutsem, for the RATIONALE-302 Investigators - Journal of Clinical Oncology 2022 被引用: 306

  14. Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics

    著者: Gang Che, Jie Yin, Wankun Wang, Yandong Luo, Yiran Chen, Xiongfei Yu, Haiyong Wang, Xiaosun Liu, Zhendong Chen, Xing Wang, Yu Chen, X Wang, Kaicheng Tang, Jiao Tang, Wei Shao, Chao Wu, Jianpeng Sheng, Qing Li, Jian Liu, Jian Liu - Drug Resistance Updates 2024 被引用: 66

  15. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

    著者: Yuanyuan Zhao, Yuxiang Ma, Aimin Zang, Ying Cheng, Yiping Zhang, Xiangcai Wang, Zhendong Chen, Song Qu, Jianbo He, Chuanben Chen, Chuan Jin, Dongyuan Zhu, Qingshan Li, Xianling Liu, Wuyun Su, Yi Ba, Yanrong Hao, Junmin Chen, Guoping Zhang, Shenhong Qu, Yong Li, Weineng Feng, Mengxiang Yang, Baorui Liu, Weiwei Ouyang, Liang Jin, Zhuang Yu, Xiaoyan Kang, Shilin Xue, Guihong Yang, Wei Yan, Yingying Yang, Zhi Liu, Yufeng Peng, Bill Fanslow, Xian Huang, Li Zhang, Hongyun Zhao - Journal of Hematology & Oncology 2023 被引用: 50

  16. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

    著者: Shun Lü, Jianying Zhou, Hong Jian, Lin Wu, Ying Cheng, Yun Fan, Jian Fang, Gongyan Chen, Zhihong Zhang, Dongqing Lv, Liyan Jiang, Rong Wu, Xiangming Jin, Xiaodong Zhang, Junhong Zhang, Conghua Xie, Gengyun Sun, Dongning Huang, Jiuwei Cui, Renhua Guo, Zhigang Han, Zhendong Chen, Jin Liang, Wu Zhuang, Xingsheng Hu, Aimin Zang, Yi Zhang, Shundong Cang, Yuanbo Lan, Xi Chen, Laiyu Liu, Xingya Li, Jun Chen, Rui Ma, Yanzhen Guo, Ping Sun, Panwen Tian, Yueyin Pan, Zhe Liu, Peiguo Cao, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang Wu - The Lancet Respiratory Medicine 2023 被引用: 71

  17. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.

    著者: Wen‐Feng Fang, Ying Cheng, Zhendong Chen, Wei Wang, Yongmei Yin, Yongsheng Li, Huiting Xu, Xingya Li, Zev A. Wainberg, Guohua Yu, Yanjun Mi, Jordi Rodon Ahnert, Xiang Wang, Xian Wang, Yina Diao, Yalan Yang, Lian Lu, Junyou Ge, Jin Li, Li Zhang - Journal of Clinical Oncology 2023 被引用: 32

  18. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

    著者: Feng Wang, Shukui Qin, Xinchen Sun, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang, Xiaoyan Lin, Xiaoming Chen, Enxiao Li, Linna Wang, Ping Yan, Jianjun Zou - Journal of Hematology & Oncology 2020 被引用: 137

  19. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

    著者: Hyun Cheol Chung, Yoon‐Koo Kang, Zhendong Chen, Yuxian Bai, Wan Zamaniah Wan Ishak, Byoung Yong Shim, Young Lee Park, Dong‐Hoe Koo, Jianwei Lu, Jianming Xu, Hong Jae Chon, Li‐Yuan Bai, Shan Zeng, Ying Yuan, Yen‐Yang Chen, Kangsheng Gu, Wen Yan Zhong, Shu Kuang, Chie‐Schin Shih, Shukui Qin - Cancer 2021 被引用: 70

  20. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer

    著者: Shukui Qin, Jin Li, Yuxian Bai, Zishu Wang, Zhendong Chen, Rui‐Hua Xu, Jianming Xu, Hongmei Zhang, Jia Chen, Ying Yuan, Tianshu Liu, Lin Yang, Haijun Zhong, Donghui Chen, Lin Shen, Chunyi Hao, Deliang Fu, Ying Cheng, Jianwei Yang, Qiong Wang, Baoli Qin, Hongming Pan, Jun Zhang, Xianhong Bai, Qingshan Zheng - Journal of Clinical Oncology 2023 被引用: 54

  21. Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy

    著者: Song Chen, Zhendong Chen, Lixue Lu, Yunpeng Zhao, Ronghui Zhou, Qiong Xie, Yongzhi Shu, Jun Lin, Xufen Yu, Yonghui Wang - European Journal of Medicinal Chemistry 2023 被引用: 33

  22. EvidenceNet: Evidence Fusion Network for Fact Verification

    著者: Zhendong Chen, Siu Cheung Hui, Fuzhen Zhuang, Lejian Liao, Fei Li, Meihuizi Jia, Jiaqi Li - Web Conference 2022, WWW 2022 被引用: 21

  23. Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer

    著者: Xinzhong Zhu, Di Dong, Zhendong Chen, Mengjie Fang, Liwen Zhang, Jiangdian Song, Dongdong Yu, Yali Zang, Zhenyu Liu, Jingyun Shi, Jie Tian - European Radiology 2018 被引用: 215

  24. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

    著者: Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek‐Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaoming Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xing Ye, Jieer Ying, Jianfeng Li, Wen Yan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao - Journal of Clinical Oncology 2022 被引用: 111